Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idecabtagene vicleucel - 2seventy bio

Next Previous
Drug Profile

Idecabtagene vicleucel - 2seventy bio

Alternative Names: Abecma; Anti-BCMA CART Cell Therapy - bluebird bio/Celgene; Anti-BCMA CART cells - bluebird bio/Celgene; bb-2121; BMS-986395; ide-cel

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator bluebird bio
  • Developer 2seventy bio; bluebird bio; Bristol-Myers Squibb; Celgene Corporation
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 25 Apr 2025 Celgene completes a phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater, Combination therapy) in the USA and Spain (IV) (NCT04855136)
  • 07 Dec 2024 Efficacy and adverse events data from the phase II KarMMa-2 trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 26 Sep 2024 2seventy bio discontinue enrollment in its phase III trial KarMMa-9 in Multiple myeloma (Adjunctive treatment) in Romania, Poland, South Korea, Japan, Italy, Israel, Greece, Germany, Denmark, Canada, Austria, USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top